Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110065 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Jiahao Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310012, China; Chemical Biology Rese…. Hauptthemen laut MEDLINE: Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Acute tubular necrosis (ATN) is a common type of acute renal failure. Recent studies have shown that NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-mediated pyroptosis in macrophages plays a crucial role in the progression of ATN. Previously, we synthesized an anti-inflammatory compound 15a based on Tanshinone IIA (Tan IIA). In the present study, we found that compound 15a exhibited a greater inhibitory effect on NLRP3-mediated pyroptosis than Tan IIA in vitro. METHODS: C57BL/6 and NLRP3-knockout (NLRP3-KO) mice were intraperitoneally injected with LPS or folic acid (FA) to develop ATN. In vitro, bone marrow-derived macrophages (BMDMs) were treated with LPS for 3 h and then treated with ATP for 0.5 h. RESULTS: We explored the mechanism by which compound 15a inhibited NLRP3 inflammasome in BMDMs as well as its renal protective effect against ATN in mice. We found that compound 15a exhibited a protective effect on mitochondria and reduced the production of mitochondrial reactive oxygen species (mtROS). Moreover, we revealed that compound 15a remarkably reduced the production of mtROS by promoting mitophagy, which resulted in the inhibition of NLRP3 inflammasome to alleviates ATN in mice. CONCLUSION: In summary, compound 15a inhibited NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate ATN. Our results identified compound 15a as a promising candidate for the treatment of NLRP3-driven ATN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310012, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical Univer…
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310012, China.
- Affiliated Yueqing Hospital,Wenzhou Medical University, Yueqing, Wenzhou, Zhejiang, 325035, China.
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310012, China. Electronic address: yklvxinting@163.com.
Zitieren
APA
Chen, J., Luo, W., Hu, C., Ren, M., Xu, H., Xu, X., Li, W., Chen, Y., Shao, J., Xiao, Z., Lv, X., & Liang, G. (2023). Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110065
Vancouver
Chen J, Luo W, Hu C, Ren M, Xu H, Xu X, et al. Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110065
BibTeX
@article{Chen2023,
author = {Chen, Jiahao and Luo, Wu and Hu, Chenghong and Ren, Miao and Xu, Haowen and Xu, Xiangwei and Li, Weifeng and Chen, Yue and Shao, Jingjing and Xiao, Zhongxiang and Lv, Xinting and Liang, Guang},
title = {Tanshinone IIA analogue 15a inhibits NLRP3-mediated inflammation by activating mitophagy in macrophages to alleviate acute tubular necrosis},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110065}
}
EUVIMED